Enterprise Wired’s Post

Timely article as we’re seeing more and more healthcare providers/medi-spas wanting to offer compounded semaglutides as part of their weight loss management.

We are in an endless pursuit to make healthcare more simple, transparent, affordable, and equitable. The role of PBMs in healthcare has historically been less transparent, creating a ripple effect of grayness across our members, pharmacists, and providers. This , when intersects with our aging population (in 2050, over 50% of us will be above the age of 65), the need for reduced prices and transparency takes the front-row seat. The White House shares the results of the first Medicare drug price negotiations, which will lead to $6 billion in savings across 10 drugs when new prices take effect in 2026 and beneficiaries could save roughly $1.5 billion in out-of-pocket costs. Meanwhile, Mark Cuban and Alex Oshmyansky, MD, PhD are accelerating the journey to less costs and affordable healthcare by reducing the middlemen Mark Cuban Cost Plus Drug Company, PBC. #healthcare #PBM #publichealth #generic #drugs #equity #health #aging #medicare

PBM's are creating adverse health incomes while reaping huge profits. A couple of "highlights" from this report: - ... increasing vertical integration and concentration has enabled the six largest PBMs to manage nearly 95 percent of all prescriptions filled in the United States. - This vertically integrated and concentrated market structure has allowed PBMs to profit at the expense of patients and independent pharmacists... - This can have dire consequences, with nearly 30 percent of Americans surveyed reporting rationing or even skipping doses of their prescribed medicines due to high costs... This is unacceptable.

Tune into the second part of this thought-provoking interview with Dr. James Robinson at the University of California, Berkeley on the impact of 340B programs and drug pricing policies. In this informative discussion, we delve into key considerations surrounding health care affordability and access. Check out the interview here. #HealthCare #DrugPricing #AccessToMedicine

The 10/2 Healthcare Labyrinth Newsfeed is live. Click below to read. Major stories: -- Trump back tracks on drug price reform -- VP debate tackles healthcare -- Senators want FTC to investigate PBM co-manufacturing -- Humana hit with low Star ratings for 2025 -- Maternal health gaps in Medicaid -- More on CVS woes -- 2027 drug price negotiations guidance #healthcare #healthcarereform #healthinsurance The Healthcare Labyrinth Marc S. Ryan 🇺🇦 https://lnkd.in/excks5UU

The 10/2 Healthcare Labyrinth Newsfeed is live. Click below to read. Major stories: -- Trump back tracks on drug price reform -- VP debate tackles healthcare -- Senators want FTC to investigate PBM co-manufacturing -- Humana hit with low Star ratings for 2025 -- Maternal health gaps in Medicaid -- More on CVS woes -- 2027 drug price negotiations guidance #healthcare #healthcarereform #healthinsurance The Healthcare Labyrinth Marc S. Ryan 🇺🇦 https://lnkd.in/edp3q4aE

Take the time to read through the recent FTC report on PBMs: https://lnkd.in/grcNSQqK What you'll learn - traditional PBMs are using harmful, destructive practices that are negatively impacting the American health care system and have been for years. - Vertical Integration - Use of overseas GPOs in order to hide data and information - Intentionally confusing, opaque contract language - A focus on PROFIT versus the ultimate care of employers and their members/patients Talk with AffirmedRx today and work with a PBM you know, like and trust - a PBM that has your best interest in mind and always does the right thing! 👏 PATIENTS over Profits

In this week's edition of Health Care Week in Review, my healthcare colleagues discuss #HHS' newly released final guidance for the second cycle of Medicare drug price negotiations, #CMS' release of the 2026 Notice of Benefit and Payment Parameters proposed rule, and more. #healthlaw

What's the latest on the FTC investigation into the PBM industry? It's interesting to note that the investigation was not initially pursued, as reported in this 2022 article. This highlights the need for a coordinated voice to raise the issue at hand. As someone who has watched PBM revenue grow every year, I've also seen the negative impact on independent pharmacies. Even health system pharmacies struggle to remain sustainable without 340B. It's astounding to learn how PBMs have benefited from 340B, which was never the program's intent. Read more about this issue in the article linked below. Let's continue the conversation on how to ensure fair practices in the PBM industry. Also this: https://lnkd.in/gn7kn83s https://lnkd.in/g58wmXbY #pbm #save340B #patientsfirst #gomarkcuban

Utilization management strategies have increased administrative burden for payers and providers and led to patient care delays. Creating pharmacy benefit transparency for all parties is critical. #patientportal #HealthcareIT #MyDrugBenefit https://lnkd.in/g8Ti-EUT